Aurinia Pharmaceuticals Inc (AUPH) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to ARINIA's ARIT Intercept Phase 1 Study Results Conference Call. Please be advised that a Q&A session will follow ARINIA's prepared remarks. You may be placed at the question queue at any time by pressing star 1 on your telephone keypad, and we ask you please limit yourselves to one question and one follow-up. I will now turn the call over to Peter Greenleaf, Chief Executive Officer of ARINIA. Please go ahead, sir. Good morning. Thank you all for joining us to discuss the results from our ARIT Intercept Phase 1 Single Ascending Dose Study. ARIT Intercept has been previously referred to as AUR 200. Joining me on the call today are Dr. Greg Keenan, our Chief Medical Officer, and Joe Miller, our Chief Financial Officer. Before beginning our discussion, I'd like to direct your attention to slide two, which contains important information regarding forward-looking statements. With that introduction, let me now turn the call over to Dr. Greg Keenan to walk you through the R-Tintercept Phase 1 study results. Greg? Thank you, Peter. It's a pleasure speaking with you today about R-Tintercept and the results of our Phase 1 single ascending dose study. R-Tintercept is a dual BAP April inhibitor. It contains a BCMA-engineered extracellular binding domain optimized for for superior affinity to BAF and APRIL. Other dual BAF and APRIL inhibitors use TASI-engineered extracellular binding domains. DCMA has a stronger natural affinity for APRIL than TASI. RX-intercept also contains an IgG4-FC domain with no appreciable effector function. Other dual BAF-APRIL inhibitors use IgG1-FC domains IgG4 is considered the least inflammatory across the IgG subclasses, in part because it poorly activates the complement system. Before we talk about our RRT intercept result...